LCRF‐0006, a small molecule mimetic of the N‐cadherin antagonist peptide ADH‐1, synergistically increases multiple myeloma response to bortezomib

LCRF‐0006, a small molecule mimetic of the N‐cadherin antagonist peptide ADH‐1, synergistically increases multiple myeloma response to bortezomib

Abstract N‐cadherin is a homophilic cell‐cell adhesion molecule that plays a critical role in maintaining vascular stability and modulating endothelial barrier permeability. Pre‐clinical studies have shown that the N‐cadherin antagonist peptide, ADH‐1, increases the permeability of tumor‐associated...

Full description

Bibliographic Details
Main Authors: Krzysztof M. Mrozik, Chee M. Cheong, Duncan R. Hewett, Jacqueline E. Noll, Khatora S. Opperman, Alaknanda Adwal, Darryl L. Russell, Orest W. Blaschuk, Kate Vandyke, Andrew C. W. Zannettino
Format: Article
Language:English
Published: Wiley 2020-06-01
Series:FASEB BioAdvances
Subjects:
combination therapy
endothelial cell
multiple myeloma
tumor‐associated vasculature
vascular permeability
Online Access:https://doi.org/10.1096/fba.2019-00073

Internet

https://doi.org/10.1096/fba.2019-00073

Similar Items